Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BGB-B3227 in Advanced or Metastatic Solid Tumors
NCT06540066Phase 1Terminated
- Sponsor
- BeiGene
- Start
- Sep 2024
- Primary completion
- Jan 2026
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 3
01
Overview
Phase 1, open-label trial of BGB-B3227 in solid tumor (advanced stage) and metastatic solid tumor (3 arms), sponsored by BeiGene. Primary endpoints: Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs) at 12 months, Maximum Tolerated Dose (MTD) or Maximum Administered Dose (MAD) at 9 months and 3 more. Started Sep 2024; status: terminated.
02
Drugs
BGB-B3227
03
Conditions
solid tumor (advanced stage)metastatic solid tumor
Beyond the preview
Go deeper on NCT06540066.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06540066.